CVM - CEL-SCI CORPORATION

[GodofStocks]

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and rheumatoid arthritis.

[GodofStocks]

Share Statistics:

Average Volume (3 month): 236,779
Average Volume (10 day): 173,800

Shares Outstanding: 74.22M
Float: 69.39M

% Held by Insiders: 6.34%
% Held by Institutions: 1.30%

[GodofStocks]

STOCH %K: 46 STA 2.5% Bull: 30

STOCH %D: 23 STA 2.5% Bear: 40

MFI: 44 STA Dollar Bull: 0

RSI: 50.5 STA Dollar Bear: 0

DI: 1.9

[GodofStocks]

Unconfirmed Earnings Expected: Wednesday, Feb 8

[JeffB]

G.O.S.

I've been watching this one for three weeks. I backed off because what I gather they did not report their financials that was due to be reported back in November. Still didn't in Dec. nor January and received a notice due to this. Am I correct?

[GodofStocks]

.06

[GodofStocks]

CEL-SCI Receives Notice From Amex Regarding Inability to File 10-Q
Friday , February 17, 2006 16:15 ET

VIENNA, Va., Feb 17, 2006 /PRNewswire-FirstCall via COMTEX/ -- CEL-SCI CORPORATION (Amex: CVM) reports the following: On January 18, 2006 CEL-SCI announced that it would not be able to file its 10-K on time and that it had asked the American Stock Exchange (AMEX) for an extension to file its 10-K for the year ending September 30, 2005. The reasons for not being able to file the 10-K on time are described in the Company's press release dated January 18, 2006. The inability to file the 10-K on time is a violation of the AMEX rules, specifically Sections 134 and 1101 of the AMEX Company Guide. As expected, CEL-SCI received a letter from the AMEX stating that the Company will have to submit a plan by February 7, 2006 advising the AMEX of action CEL-SCI has taken, or will take, that would allow the Company to file the 10-K by no later than March 20, 2006. CEL-SCI submitted this plan to the AMEX on February 7, 2006. The plan indicated that it would file the 10-K by March 20, 2006. Since CEL-SCI does not have a completed 10-K, CEL-SCI was unable to file its quarterly report (10-Q) for the period ending December 31, 2005 in a timely manner either. This constitutes an additional deficiency under Section 134 and 1101 of the AMEX rules. CEL-SCI will now have to submit a plan to the AMEX by March 3, 2006 advising the AMEX of action CEL-SCI has taken, or will take, that would allow the Company to file the 10-Q by no later than April 6, 2006. If the AMEX accepts CEL-SCI's plans, CEL-SCI can maintain its AMEX listing during that time subject to the periodic determination by the AMEX that CEL-SCI is making progress consistent with the plan. If CEL-SCI's plan is not accepted, CEL-SCI will be subject to delisting proceedings.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward- looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation

COMPANY CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460; or INVESTOR
RELATIONS: Mike Lucci of Lucci Financial Group, LLC, +1-248-723-3330, for CEL-SCI
Corporation

http://www.prnewswire.com

Copyright (C) 2006 PR Newswire. All rights reserved.

[GodofStocks]

CVM: Volume Spike; 63% > 20-adsv, Stock +9.09%
Friday , February 17, 2006 13:50 ET

This is the 2nd VOLUME alert for CVM in the past 7 calendar days.

Trading for Cel-Sci Corporation (AMEX: CVM) has been heavier than usual in today's session. By 13:50 ET, the stock had already traded 305,600 shares via 52 trades. The cumulative volume is 62.52% above its 20-day average of 188,040. Normally the stock experiences around 36 individual trades per session.

So far, today's volume surge has caused a net rise in CVM's stock price. At the time of this alert, the stock was trading at $0.600, up $0.050 (+9.09%).

One year ago, the Company's shares closed at $0.730. The price has declined more than 17 percent since then.

Over the last 10 trading session CVM has traded in a range between $0.500 and $0.580 and is currently trading 23.08% below its 52-week high of $0.780 set on February 22,2005 and 36.36% above its 52-week low of $0.440 from October 14,2005.

In the previous 3 sessions, CVM trading has displayed a mixed trend. Closing results have been as follows:

February 16, 2006 --- closed at $0.550 up $0.010 (+1.85%) on 353,800 shares
February 15, 2006 --- closed at $0.540 even for the day on 83,700 shares
February 14, 2006 --- closed at $0.540 up $0.010 (+1.89%) on 132,000 shares

The Company last released news on February 14, 2006:

"CEL-SCI Provides Estimated Financial Results for First Quarter 2006"

CEL-SCI CORPORATION
Engaged in the research and development of drugs and vaccines. The company's primary product utilizes a proprietary cell culture technology.

[GodofStocks]

HUGE volume today, up to .75 during the day, closed at .66.

[GodofStocks]

CVM: Multikine Treatment Increases Survival in Cancer Patients
Tuesday , February 21, 2006 10:09 ET

CEL-SCI Corporation (CVM) announces positive results from a long-term follow-up study of head & neck cancer patients treated with its drug Multikine(R) in a Phase II clinical trial. The follow-up study indicated that Multikine treatment resulted in a substantial increase in the survival of patients. In addition, Multikine treatment also improved local regional control of the patients' tumors. Improved local regional control of the tumor is considered by many surgeons and oncologists to be an important measurement of the success of a head & neck cancer drug. Both survival and local regional control of the tumor are stated endpoints in CEL-SCI's planned Phase III clinical trial.